<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181218042033N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-15</date_registration>
      <primary_sponsor>Vice-Chancellery for Research Hormozgan University of Medical Sciences</primary_sponsor>
      <public_title>Betadine versus metronidazole gel for post-cesarean section infections</public_title>
      <acronym></acronym>
      <scientific_title>Vaginal preparation with povidone-iodine versus metronidazole for preventing post-Cesarean infections</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>426</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62534</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple randomization with individuals as units of randomization along with allocation concealment: 426 unclear envelopes and 426 cards with the names of the groups (A, B, C) will be prepared (142 cards for each group). The cards will be put into the envelopes and the envelopes will be sealed and provided to the investigator. Upon entrance of each patient to the study, the envelopes will be shuffled and one will randomly be selected. The patient will be allocated to group A, B, or C based on the card inside the selected envelope, Blinding description: The study will be single-blind, so that the investigator in charge of outcome assessing will be unaware of patient groupings. Therefore, blinding will only be done for the outcome-assessor and the patients, the healthcare providers, and the statistician will know patient groupings.</study_design>
      <phase>3</phase>
      <hc_freetext>Post-cesarean section infection.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Abdominal skin preparation using 7.5% povidone-iodine (Iran Najo Co., Tehran, Iran) and then draping using sterile surgical drapes before cesarean section. Intervention 2: Intervention group 1: 10 min to 2 hours prior to cesarean section, the whole vagina as well as the anterior and posterior fornices will be washed in a 360-degree rotational manner for 30 seconds, using two pieces of sterile gauze soaked in 7.5% povidone-iodine (Iran Najo Co., Tehran, Iran). Then abdominal skin preparation will be done using 7.5% povidone-iodine and draping using sterile surgical drapes before cesarean section. Intervention 3: Intervention group 2: 2 hours prior to cesarean section, 5 g metronidazole gel 0.75% (Pars Darou, Iran) will be used for vaginal preparation. Then abdominal skin preparation will be done using 7.5% povidone-iodine (Iran Najo Co., Tehran, Iran) and draping using sterile surgical drapes before cesarean section.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nazanin Abdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. Ali Shariati Hospital, Shahid Naser Blvd., Next to the Revolutionary Court, Bandar Abbas, Hormozgan</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7916613885</zip>
        <telephone>+98 76 3333 5934</telephone>
        <email>abdinazanain834@gmail.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nazanin Abdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. Ali Shariati Hospital, Shahid Naser Blvd., Next to the Revolutionary Court, Bandar Abbas, Hormozgan</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7916613885</zip>
        <telephone>+98 76 3333 5934</telephone>
        <email>abdinazanin834@gmail.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Elective cesarean section
Singleton pregnancy</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Severe bleeding
Hypersensitivity to metronidazole or povidone-iodine
Active genital herpes
Severe anemia (hematocrit &lt;30%)
Human immunodeficiency virus (HIV) infection
Body mass index (BMI) &gt;30 kg/m2
Preeclampsia
Diabetes mellitus
Antibiotic or corticosteroid use
Rupture of membranes
Chorioamnionitis
Fever due to any cause prior to cesarean section (temperature &gt;38 C)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O86.12</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Endometritis following delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Abdominal skin preparation using 7.5% povidone-iodine (Iran Najo Co., Tehran, Iran) and then draping using sterile surgical drapes before cesarean section</i_keyword>
      <i_keyword>Intervention group 1: 10 min to 2 hours prior to cesarean section, the whole vagina as well as the anterior and posterior fornices will be washed in a 360-degree rotational manner for 30 seconds, using two pieces of sterile gauze soaked in 7.5% povidone-iodine (Iran Najo Co., Tehran, Iran). Then abdominal skin preparation will be done using 7.5% povidone-iodine and draping using sterile surgical drapes before cesarean section.</i_keyword>
      <i_keyword>Intervention group 2: 2 hours prior to cesarean section, 5 g metronidazole gel 0.75% (Pars Darou, Iran) will be used for vaginal preparation. Then abdominal skin preparation will be done using 7.5% povidone-iodine (Iran Najo Co., Tehran, Iran) and draping using sterile surgical drapes before cesarean section.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Endometritis. Timepoint: Up to 15 days after cesarean section. Method of measurement: Clinical examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Wound infection. Timepoint: Up to 15 days after cesarean section. Method of measurement: Clinical examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice-Chancellery for Research Hormozgan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-10</approval_date>
        <contact_name>Ethics Committee of Hormozgan University of Medical Sciences</contact_name>
        <contact_address>Hormozgan University of Medical Sciences, Chamran Blvd., Bandar Abbas, Iran Bandar Abbas Hormozgan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
